Pharmaceuticals News and Research

RSS

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

20 Oct 2010

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.

19 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.

19 Oct 2010

Research calls for better environmental risk assessments of pharmaceuticals

The strategies used to assess the environmental risks posed by pharmaceuticals are not enough to protect natural microbial communities, reveals a researcher from the University of Gothenburg (Sweden) who is calling for better environmental risk assessments.

19 Oct 2010

U.S. patient monitoring market to reach $4 billion by 2017: iData Research

According to a new report by iData Research the leading global authority in medical device and pharmaceutical market research, the U.S. patient monitoring market is expected to reach almost $4 billion by 2017.

19 Oct 2010

Novartis to implement Veeva CRM for global deployments

Veeva Systems announced today that Novartis Pharmaceuticals AG, a world leader in the research, development, manufacturing and marketing of products to protect and improve health and well-being, has chosen Veeva CRM® for various global deployments.

19 Oct 2010

d-Wise announces opening of office in the UK

d-Wise, provider of powerful business solutions for unique challenges of Life Sciences & Healthcare industries, announced the opening of its office in the UK. The company's UK efforts are spearheaded by James McDermott, a leader and key player in the pharmaceutical and biotechnology outsourcing arena.

19 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

First Edition: October 19, 2010

Today's major health policy headlines include reports about the latest developments in Virginia's court challenge against the health law, a U.S. government lawsuit targeting Michigan Blue Cross Blue Shield for anti-trust activities and a study about the Department of Health and Human Services' Hospital Compare.

19 Oct 2010

Pseudobulbar affect impacts majority of stroke survivors, but few have any understanding of condition

A survey released today by National Stroke Association shows that 53 percent of stroke survivor respondents suffer from symptoms of another neurologic condition called pseudobulbar affect (PBA), a condition thought to be caused by structural damage in the brain due to injury or disease. PBA causes involuntary and unpredictable outbursts of laughing or crying, often in socially inappropriate situations. Even though a significant proportion of stroke survivors suffer from PBA, fewer than one in five are familiar with the condition.

19 Oct 2010

ISI launches initiative to create translation glossary for healthcare providers

Phrases like "Grandfathered Health Plan" or "Biosimilar Biological Products" are hard enough to understand in English, let alone trying to accurately translate those concepts into Spanish, Chinese or any other of the dozens of languages in which healthcare providers must communicate.

19 Oct 2010

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

UnitedHealth Group consolidated third quarter revenues increase 9% to $23.7 billion

UnitedHealth Group today reported third quarter results, including strong revenue growth in both its Health Benefits and Health Services business groups. Third quarter 2010 net earnings were $1.14 per share. Key performance metrics and costs were in line with or better than Company expectations.

19 Oct 2010

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

MPI of Biochemistry and GSK collaborate in development of new drugs for type 2 diabetes

The recently signed cooperation agreement between the MPI of Biochemistry and GSK pursues the objective of developing innovative new drugs. The joint research and development work is based on the research findings of Axel Ullrich, Director at the MPI of Biochemistry.

19 Oct 2010

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Finding a drug that can cross the blood-brain barrier is the bane of drug development for Alzheimer's disease and other neurological disorders of the brain. A new Penn study, published this week in the Journal of Neuroscience, has found and tested in an animal model of Alzheimer's disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.

19 Oct 2010

Researchers identify new mechanism that could help develop effective chemotherapy drug

Information on proteins is critical for understanding how cells function in health and disease. But while regular proteins are easy to extract and study, it is far more difficult to gather information about membrane proteins, which are responsible for exchanging elements essential to our health, like copper, between a cell and its surrounding tissues.

19 Oct 2010

Survey reveals impact of insomnia during menopause

Results released today from a survey of more than 900 women, who experienced sleep problems during menopause, shed light on the impact insomnia can have during this time in a woman's life. The survey also revealed that for many women, insomnia during menopause is not proactively addressed by their healthcare provider (HCP) and that often times, women don't communicate their symptoms to their HCP.

19 Oct 2010

Transcept announces Intermezzo tablet preliminary data for insomnia

Transcept Pharmaceuticals, Inc. today announced its preliminary analysis of data from the recently completed Intermezzo 3.5 mg (zolpidem tartrate sublingual tablet) highway driving study.

19 Oct 2010

Pharmaceuticals News and Research

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

BioMarin announces BMN-111 program for treatment of achondroplasia

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Research calls for better environmental risk assessments of pharmaceuticals

U.S. patient monitoring market to reach $4 billion by 2017: iData Research

Novartis to implement Veeva CRM for global deployments

d-Wise announces opening of office in the UK

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

First Edition: October 19, 2010

Pseudobulbar affect impacts majority of stroke survivors, but few have any understanding of condition

ISI launches initiative to create translation glossary for healthcare providers

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

UnitedHealth Group consolidated third quarter revenues increase 9% to $23.7 billion

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

MPI of Biochemistry and GSK collaborate in development of new drugs for type 2 diabetes

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Researchers identify new mechanism that could help develop effective chemotherapy drug

Survey reveals impact of insomnia during menopause

Transcept announces Intermezzo tablet preliminary data for insomnia

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence